Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1

Ruiwen Zhang, Robert B Diasio, Zhihong Lu, Tiepu Liu, Zhiwei Jiang, Wayne M. Galbraith, Sudhir Agrawal

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

An antisense oligodeoxynucleotide phosphorothioate, namely gene expression modulator 91 (GEM 91), has been demonstrated to have significant anti-human immunodeficiency virus activity in various tissue culture models. The present study was undertaken to determine the pharmacokinetics and tissue distribution of GEM 91 in rats following i.v. bolus administration of 35S-radiolabeled GEM 91. Plasma disappearance curves for GEM 91-derived radioactivity could be described by the sum of two exponentials, with half-lives (mean ± SEM) of 0.95 (± 0.07) and 47.57 (± 14.48) hr. Urinary excretion represented the major pathway of elimination of GEM 91, with 26.67 ± 6.46% (mean ± SD) of the administered dose excreted within 24 hr and 58.12 ± 4.36% over 240 hr after GEM 91 administration. Fecal excretion was a minor pathway of elimination of GEM 91 with 1.4 ± 0.62% (mean ± SD) of the administered dose excreted over 24 hr and 8.54 ± 0.64% over 240 hr. A wide tissue distribution of GEM 91 was observed. During the initial 30 min, the highest levels of tissue radioactivity were found in the kidney, liver, spleen, lungs, and heart. Radioactivity was retained over longer time periods in the kidneys, liver, heart, and intestine. Analyses of the extracted radioactivities from plasma, kidney, and liver by gel electrophoresis showed the presence of both intact GEM 91 and degradative products with smaller molecular weights. Radioactivity in urine was found to be degradative metabolites of GEM 91. Based on the experimental data, pharmacokinetic parameters for GEM 91 in each tissue and biological fluids were calculated using computer-based two-compartmental i.v. bolus or absorption models. This study is important not only in providing the basis for future studies of GEM 91 in humans, but also in understanding the pharmacology and toxicology of antisense oligodeoxynucleotide phosphorothioates, in general.

Original languageEnglish (US)
Pages (from-to)929-939
Number of pages11
JournalBiochemical Pharmacology
Volume49
Issue number7
DOIs
StatePublished - Mar 30 1995
Externally publishedYes

Fingerprint

Pharmacokinetics
Oligodeoxyribonucleotides
Tissue Distribution
Viruses
HIV-1
Rats
Tissue
Radioactivity
Therapeutics
Liver
Kidney
GEM91
Plasmas
Tissue culture
Metabolites
Electrophoresis
Toxicology
Intestines
Spleen
Molecular Weight

Keywords

  • antisense oligodeoxynucleotide phosphorothioate
  • GEM 91
  • HIV-1
  • metabolism
  • pharmacokinetics
  • tissue disposition

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. / Zhang, Ruiwen; Diasio, Robert B; Lu, Zhihong; Liu, Tiepu; Jiang, Zhiwei; Galbraith, Wayne M.; Agrawal, Sudhir.

In: Biochemical Pharmacology, Vol. 49, No. 7, 30.03.1995, p. 929-939.

Research output: Contribution to journalArticle

@article{22ef242e0ab24c158e3a5bac19ed08f8,
title = "Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1",
abstract = "An antisense oligodeoxynucleotide phosphorothioate, namely gene expression modulator 91 (GEM 91), has been demonstrated to have significant anti-human immunodeficiency virus activity in various tissue culture models. The present study was undertaken to determine the pharmacokinetics and tissue distribution of GEM 91 in rats following i.v. bolus administration of 35S-radiolabeled GEM 91. Plasma disappearance curves for GEM 91-derived radioactivity could be described by the sum of two exponentials, with half-lives (mean ± SEM) of 0.95 (± 0.07) and 47.57 (± 14.48) hr. Urinary excretion represented the major pathway of elimination of GEM 91, with 26.67 ± 6.46{\%} (mean ± SD) of the administered dose excreted within 24 hr and 58.12 ± 4.36{\%} over 240 hr after GEM 91 administration. Fecal excretion was a minor pathway of elimination of GEM 91 with 1.4 ± 0.62{\%} (mean ± SD) of the administered dose excreted over 24 hr and 8.54 ± 0.64{\%} over 240 hr. A wide tissue distribution of GEM 91 was observed. During the initial 30 min, the highest levels of tissue radioactivity were found in the kidney, liver, spleen, lungs, and heart. Radioactivity was retained over longer time periods in the kidneys, liver, heart, and intestine. Analyses of the extracted radioactivities from plasma, kidney, and liver by gel electrophoresis showed the presence of both intact GEM 91 and degradative products with smaller molecular weights. Radioactivity in urine was found to be degradative metabolites of GEM 91. Based on the experimental data, pharmacokinetic parameters for GEM 91 in each tissue and biological fluids were calculated using computer-based two-compartmental i.v. bolus or absorption models. This study is important not only in providing the basis for future studies of GEM 91 in humans, but also in understanding the pharmacology and toxicology of antisense oligodeoxynucleotide phosphorothioates, in general.",
keywords = "antisense oligodeoxynucleotide phosphorothioate, GEM 91, HIV-1, metabolism, pharmacokinetics, tissue disposition",
author = "Ruiwen Zhang and Diasio, {Robert B} and Zhihong Lu and Tiepu Liu and Zhiwei Jiang and Galbraith, {Wayne M.} and Sudhir Agrawal",
year = "1995",
month = "3",
day = "30",
doi = "10.1016/0006-2952(95)00010-W",
language = "English (US)",
volume = "49",
pages = "929--939",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1

AU - Zhang, Ruiwen

AU - Diasio, Robert B

AU - Lu, Zhihong

AU - Liu, Tiepu

AU - Jiang, Zhiwei

AU - Galbraith, Wayne M.

AU - Agrawal, Sudhir

PY - 1995/3/30

Y1 - 1995/3/30

N2 - An antisense oligodeoxynucleotide phosphorothioate, namely gene expression modulator 91 (GEM 91), has been demonstrated to have significant anti-human immunodeficiency virus activity in various tissue culture models. The present study was undertaken to determine the pharmacokinetics and tissue distribution of GEM 91 in rats following i.v. bolus administration of 35S-radiolabeled GEM 91. Plasma disappearance curves for GEM 91-derived radioactivity could be described by the sum of two exponentials, with half-lives (mean ± SEM) of 0.95 (± 0.07) and 47.57 (± 14.48) hr. Urinary excretion represented the major pathway of elimination of GEM 91, with 26.67 ± 6.46% (mean ± SD) of the administered dose excreted within 24 hr and 58.12 ± 4.36% over 240 hr after GEM 91 administration. Fecal excretion was a minor pathway of elimination of GEM 91 with 1.4 ± 0.62% (mean ± SD) of the administered dose excreted over 24 hr and 8.54 ± 0.64% over 240 hr. A wide tissue distribution of GEM 91 was observed. During the initial 30 min, the highest levels of tissue radioactivity were found in the kidney, liver, spleen, lungs, and heart. Radioactivity was retained over longer time periods in the kidneys, liver, heart, and intestine. Analyses of the extracted radioactivities from plasma, kidney, and liver by gel electrophoresis showed the presence of both intact GEM 91 and degradative products with smaller molecular weights. Radioactivity in urine was found to be degradative metabolites of GEM 91. Based on the experimental data, pharmacokinetic parameters for GEM 91 in each tissue and biological fluids were calculated using computer-based two-compartmental i.v. bolus or absorption models. This study is important not only in providing the basis for future studies of GEM 91 in humans, but also in understanding the pharmacology and toxicology of antisense oligodeoxynucleotide phosphorothioates, in general.

AB - An antisense oligodeoxynucleotide phosphorothioate, namely gene expression modulator 91 (GEM 91), has been demonstrated to have significant anti-human immunodeficiency virus activity in various tissue culture models. The present study was undertaken to determine the pharmacokinetics and tissue distribution of GEM 91 in rats following i.v. bolus administration of 35S-radiolabeled GEM 91. Plasma disappearance curves for GEM 91-derived radioactivity could be described by the sum of two exponentials, with half-lives (mean ± SEM) of 0.95 (± 0.07) and 47.57 (± 14.48) hr. Urinary excretion represented the major pathway of elimination of GEM 91, with 26.67 ± 6.46% (mean ± SD) of the administered dose excreted within 24 hr and 58.12 ± 4.36% over 240 hr after GEM 91 administration. Fecal excretion was a minor pathway of elimination of GEM 91 with 1.4 ± 0.62% (mean ± SD) of the administered dose excreted over 24 hr and 8.54 ± 0.64% over 240 hr. A wide tissue distribution of GEM 91 was observed. During the initial 30 min, the highest levels of tissue radioactivity were found in the kidney, liver, spleen, lungs, and heart. Radioactivity was retained over longer time periods in the kidneys, liver, heart, and intestine. Analyses of the extracted radioactivities from plasma, kidney, and liver by gel electrophoresis showed the presence of both intact GEM 91 and degradative products with smaller molecular weights. Radioactivity in urine was found to be degradative metabolites of GEM 91. Based on the experimental data, pharmacokinetic parameters for GEM 91 in each tissue and biological fluids were calculated using computer-based two-compartmental i.v. bolus or absorption models. This study is important not only in providing the basis for future studies of GEM 91 in humans, but also in understanding the pharmacology and toxicology of antisense oligodeoxynucleotide phosphorothioates, in general.

KW - antisense oligodeoxynucleotide phosphorothioate

KW - GEM 91

KW - HIV-1

KW - metabolism

KW - pharmacokinetics

KW - tissue disposition

UR - http://www.scopus.com/inward/record.url?scp=0028934855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028934855&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(95)00010-W

DO - 10.1016/0006-2952(95)00010-W

M3 - Article

C2 - 7741765

AN - SCOPUS:0028934855

VL - 49

SP - 929

EP - 939

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -